Travere therapeutics submits supplemental new drug application to the u.s. food and drug administration seeking full approval of filspari® (sparsentan) for the treatment of iga nephropathy (igan)

Travere announces submission of an snda to the fda for conversion of existing us accelerated approval of filspari (sparsentan) in igan to full approval.

TVTX Ratings Summary

TVTX Quant Ranking